Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2016', provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics. The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Overview 8 Therapeutics Development 9 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Stage of Development 9 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Therapy Area 10 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Indication 11 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Companies 15 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Universities/Institutes 18 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment 20 Assessment by Monotherapy/Combination Products 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development 27 Bayer AG 27 Boehringer Ingelheim GmbH 28 Ironwood Pharmaceuticals Inc 29 NicOx SA 30 SynZyme Technologies LLC 31 Topadur Pharma AG 32 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles 33 A-8R - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 BAY sGCact - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 BAY-1636183 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 BI-703704 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 hydroxyurea - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 IW-1701 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 IW-1973 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 IWP-953 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 naproxcinod - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 NCX-1021 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 NCX-1653 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 NCX-250 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 NCX-422 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 NCX-429 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 NCX-434 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 NCX-466 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 NCX-470 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 NCX-667 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 nitric oxide - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Q-201 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 riociguat - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule to Activate soluble guanylate cyclase for Hypertension and Parenchymal Hemorrhage - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 TOPN-53 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Vacno - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 vericiguat - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Projects 67 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products 73 Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Featured News & Press Releases 74 Oct 18, 2016: Bayer to Present Data in Pulmonary Arterial Hypertension at the 2016 Annual Meeting of the American College of Chest Physicians 74 Sep 28, 2016: Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure 74 Sep 16, 2016: Withdrawal of the marketing authorisation application for Adempas (riociguat) 75 Jun 24, 2016: Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia 77 May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference 78 May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias 80 Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 80 Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IWP-953 at Upcoming Scientific Conferences 81 Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 81 Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA 82 Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1973 83 Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1701 83 Oct 22, 2015: Bayer to Present Pulmonary Arterial Hypertension Data at American College of Chest Physicians Annual Meeting 84 Oct 07, 2015: Bayer to Evaluate Riociguat in Children Suffering from Pulmonary Arterial Hypertension 85 Jul 22, 2015: Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Assessment by Monotherapy/Combination Products, H2 2016 20 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Pipeline by Bayer AG, H2 2016 27 Pipeline by Boehringer Ingelheim GmbH, H2 2016 28 Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 29 Pipeline by NicOx SA, H2 2016 30 Pipeline by SynZyme Technologies LLC, H2 2016 31 Pipeline by Topadur Pharma AG, H2 2016 32 Dormant Projects, H2 2016 67 Dormant Projects (Contd..1), H2 2016 68 Dormant Projects (Contd..2), H2 2016 69 Dormant Projects (Contd..3), H2 2016 70 Dormant Projects (Contd..4), H2 2016 71 Dormant Projects (Contd..5), H2 2016 72 Discontinued Products, H2 2016 73
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.